With a win in lung cancer, biotech’s wealthiest outsider surfs to new heights

Taking stock of the drug industry, from the lab to the medicine chest

September 9, 2024 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Wikimedia Commons STAT+ | With a win in lung cancer, biotech's wealthiest outsider surfs to new heights Summit's lung cancer treatment has wowed researchers. The CEO behind it is a living challenge to the assumptions of many in biotech. By Matthew Herper STAT+ | Relay discloses encouraging results for experimental breast cancer treatment Relay is planning a late-stage trial comparing its breast cancer drug to a rival treatment from AstraZeneca. By Angus Chen STAT+ | Merck executive plays down impact of new lung cancer drug data on Keytruda "I see these results as important, but preliminary," Chief Medical Officer Eliav Barr told STAT, reacting to a Phase 3 clinical trial involving ivonescimab. By Adam Feuerstein Adobe STAT+ | RayzeBio, Dice alums raise $370 million for new autoimmune startup San Diego-based Candid Therapeutics, helmed by former RayzeBio CEO Ken Song, will test two promising autoimmune drug candidates. By Allison DeAngelis

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2024, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser